TechnologyEnveda secures $311 million to bring nature-derived drugs into clinical trials
TechCrunch reports that the round valued the AI biotech at $2 billion. The company is testing drugs aimed at treating skin conditions and preserving weight loss after people stop taking GLP-1s.
TLDR
Enveda secured $311 million to bring more nature-derived drugs into clinical trials, TechCrunch reports. The outlet says the round valued the AI biotech at $2 billion and that its ongoing drug testing targets skin conditions and preserving weight loss after people stop taking GLP-1s.
Enveda secures $311 million to bring nature-derived drugs into clinical trials
TechCrunch reports that the round valued the AI biotech at $2 billion. The company is testing drugs aimed at treating skin conditions and preserving weight loss after people stop taking GLP-1s.